DTIL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
DTIL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Precision BioSciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $23.64 Mil. Precision BioSciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $7.41 Mil. Precision BioSciences's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $37.21 Mil. Precision BioSciences's debt to equity for the quarter that ended in Mar. 2024 was 0.83.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Precision BioSciences's Debt-to-Equity or its related term are showing as below:
During the past 7 years, the highest Debt-to-Equity Ratio of Precision BioSciences was 4.84. The lowest was 0.10. And the median was 0.25.
The historical data trend for Precision BioSciences's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Precision BioSciences Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Debt-to-Equity | Get a 7-Day Free Trial | - | 0.24 | 0.10 | 0.41 | 1.66 |
Precision BioSciences Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Debt-to-Equity | Get a 7-Day Free Trial | 0.66 | 0.82 | 0.82 | 1.66 | 0.84 |
For the Biotechnology subindustry, Precision BioSciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Precision BioSciences's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Precision BioSciences's Debt-to-Equity falls into.
Debt to Equity measures the financial leverage a company has.
Precision BioSciences's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Debt to Equity | = | Total Debt | / | Total Stockholders Equity | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Stockholders Equity | |
= | (23.545 | + | 7.723) | / | 18.861 | |
= | 1.66 |
Precision BioSciences's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as
Debt to Equity | = | Total Debt | / | Total Stockholders Equity | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Stockholders Equity | |
= | (23.642 | + | 7.411) | / | 37.206 | |
= | 0.83 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Precision BioSciences (NAS:DTIL) Debt-to-Equity Explanation
In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.
Be Aware
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Thank you for viewing the detailed overview of Precision BioSciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
J. Jefferson Smith | 10 percent owner | C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM NC 27701 |
Alan List | officer: Chief Medical Officer | C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, DURHAM NC 27701 |
Michael Amoroso | director, officer: President and CEO | 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019 |
Dario Scimeca | officer: General Counsel | C/O PRECISION BIOSCIENCES, INC., 302 E. PETTIGREW STREET, SUITE A-100, DURHAM NC 27701 |
John Alexander Kelly | officer: Interim CFO | C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022 |
Pharma Ag Novartis | 10 percent owner | LICHTSTRASSE 35, CH-4002, BASEL V8 |
Ag Novartis | 10 percent owner | LICHTSTRASSE 35, BASEL V8 CH 4056 |
Derek Jantz | director, 10 percent owner, officer: Chief Scientific Officer | C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM NC 27701 |
Melinda Brown | director | 10 HUDSON YARDS, NEW YORK NY 10001 |
Shari Lisa Pire | director | C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, DURHAM NC 27701 |
Samuel C. Wadsworth | director | C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
David S. Thomson | officer: Chief Development Officer | C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM NC 27701 |
Stanley Frankel | director | C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, DURHAM NC 27701 |
Matthew R. Kane | director, 10 percent owner, officer: President and CEO | C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM NC 27701 |
Shane Barton | officer: VP & Corporate Controller | C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, DURHAM NC 27701 |
From GuruFocus
By Business Wire • 06-22-2023
By Business Wire Business Wire • 05-02-2023
By Business Wire • 09-06-2023
By Business Wire • 11-13-2023
By Business Wire Business Wire • 05-08-2023
By Business Wire • 12-13-2023
By Business Wire • 11-30-2023
By Business Wire Business Wire • 06-05-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.